Republic Republic Republic
  • Log in
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Republic Venture Opportunities for accredited investors
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Log in Sign up

Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US
  • Log in
  • Sign up
All investors
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Accredited only
Republic Venture Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Spotlight deal
ASM Capital Whiskey Fund
ASM Capital Whiskey Fund
Funding the emergence of American Single Malt
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets
Sharedrops Gift equity as a reward
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services

Supersapiens isn't accepting new investments

Supersapiens ’s deadline was April 29, 2023

Follow the company to stay updated on their progress, including future investment opportunities


Explore new investment opportunities:
View companies raising now
Campaign ended
Logo of Supersapiens

Supersapiens

Real-time biometric insights | Unlocking human health and performance
SaaS Women Founders Wellbeing & Longevity Fitness Healthtech Biotechnology Wearables
Facebook Telegram Twitter LinkedIn
Featured image of Supersapiens
Fully Funded
$1,235,000
Raised
376
Investors
Successfully funded and closed on April 29, 2023.
Invest in Supersapiens

Open for investment

Investors in Supersapiens also invested in these companies. View more
Logo of EigenQ

EigenQ

A Smart Move for Forward-Thinking Investors! EigenQ ...

Republic Funding Portal · Reg CF
Logo of Muvr

Muvr

Fueling the Future of AI-Powered Logistics

Republic Funding Portal · Reg CF
Loading...
Pitch Updates 2 Reviews 82
Invest Invest in Supersapiens
Facebook Telegram Twitter LinkedIn
Closed on April 29, 2023. Information may not be up-to-date. Campaign closed on April 29, 2023. Information displayed may not be up-to-date.
Problem Solution Product Traction Customers Biz. model Market Competition Vision and strategy Funding Founders
About Team Press

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by TT1 Products, Inc. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Supersapiens Security TT1 Products (Supersapiens) Form C .pdf
Loading

Hear from some of the 376 investors in Supersapiens


Show more

Highlights


  • Real-time glucose monitoring platform for optimizing health and performance
  • Metabolic insights, assistance, and education for athletes
  • $2M 2022 revenue | 15,000+ users
  • World's largest glucose dataset (non-diabetic): 800M+ data points
  • Used by Olympians, F1, UEFA, NBA, PGA, NFL, NHL, MLB, pro cyclist & Ironman
  • Strategic partnership with industry leader Abbott

Problem


Glucose is critical to human health and performance

Perfomance

  • Lack of fueling feels like a lack of fitness. It is not. There is a direct correlation between glucose levels and performance

  • Athletes must monitor and maintain appropriate glucose levels for optimal performance, health and safety

  • An athlete with a healthy liver and pancreas will regulate blood glucose through two main hormones — insulin and glucagon — in the pursuit of achieving homeostasis

  • When the body is not fueled properly, glucose levels can drop below 70 mg/dL (hypoglycemia) and the body may suffer from fatigue, loss of focus, total energy depletion, and more

  • Hypoglycemic events can go unrecognized due to subtleties of performance degradation – focus, concentration, coordination – that can be overlooked as pertaining to a shortage of fuel


Solution


Real-time metabolic visibility

Proactive education on lifestyle changes,
exercise & nutritional assistance

Supersapiens is a sports technology ecosystem that provides a window into the body's glucose metabolism — the foundation for human function. The platform provides real-time data and insights to optimize glucose and performance.

Fueled by a partnership with Abbott, Supersapiens is the exclusive global distributor of the only minute-by-minute glucose sensor designed to help athletes, coaches, nutritionists, and trainers make better science-based decisions.

Findings show CGM supports self-care behaviors:
  • Checking glucose consistently
  • Adjusting eating
  • Engaging generally in better overall self-care, like improved nutrition and exercise


Product


Supersapiens: next-gen insights empowering
human performance

  • As the body’s preferred energy source, glucose is key in athletic performance
  • Glucose stability is the foundation for consistent performance, and Supersapiens is the platform for glucose stability
  • Goals are foundational for progress, and Supersapiens unlocks achieving goals
  • Supersapiens is the synthesis of science and sport – helping athletes understand energy, mood, food, sleep, and movement to accelerate their journey to progress




App: next-level performance
starts with better data


  • Understand the fuel your body responds best to and what glucose levels match your peak performance, so you can determine your personalized glucose response and fueling strategy – helping you unlock your full athletic potential
  • Supersapiens glucose monitoring experience enables athletes to understand the efficacy of their nutrition choices during training and competition, and therefore inform athletes about how to fuel appropriately —filling their glycogen stores prior to competition and knowing when to replenish to maintain athletic performance
  • Personalized and easy-to-use nutrition and activity inputs break down glucose readings into phases for easily digestible information and insights

Data dashboard:
a window into your body


  • Recommendations
    Provides personal recommendations on activity, sleep, nutrition, and fasting by analyzing the context of glucose
  • Accuracy & convenience
    Unlocks the most accurate and scalable biosensor, developed by our partner, Abbott
  • Decision validation
    Presents minute-to-minute personal data readings 24/7 to help you manage your body in real-time
  • Health span
    Empowers you to become more active, naturally improving health outcomes — this is your journey to becoming a Supersapien


Platform integrations:
accelerating insights


  • Third-party integrations with other leading health and fitness platforms provide additional layers of insights, all grounded in glucose
  • Integrations enhance the power of the Supersapiens app and engage users in between sensor use
  • Integration example: a runner can overlay pace from a Garmin watch with glucose levels to see that when their blood glucose dropped, pace decreased — allowing the runner to properly refuel before crashing and maintain performance

Sensor: a molecular lab
on your arm


  • Developed for clinical use & adapted for athlete: the Abbott Libre Sense Glucose Sport Biosensor is backed by Abbott’s pioneering track record of breakthrough innovation, medical firsts, and clinical credibility
  • Libre Sense Glucose Sport Biosensor, with the Supersapiens app, enables real-time visibility in the body’s molecular glucose data, unlocking first-of-its-kind insights into athletic fueling — so you can make the right choices to achieve your goals
  • Each sensor has an ultra thin filament just under the skin where it measures glucose levels in the interstitial fluid, which is the most relevant for athletes

Traction


$2M 2022 revenue
15k+ users


  • Supersapiens has the world’s largest glucose data set for non-diabetic population, with over 3.1M events, over 870M unique data points & 5x+ the daily data points of the closest competitor
  • World class athletes continue to achieve exceptional results, having drawn actionable insights from the Supersapiens platform
  • Only non-diabetic glucose sensor with regulatory approval (EU) and pending US FDA approval (2024E)
  • US expansion opportunity — Supersapiens is well-positioned for commercial launch and exponential growth in the world’s largest wearable fitness market
  • The strategic partnership and exclusive arrangement with Abbott provides Supersapiens with reliable and accurate data for insights, and the companies continue to jointly innovate, research, and develop technology

Revenue built to scale*



Milestones & trajectory



Key statistics


  • Headquarters: Atlanta, GA
  • Founded: 2019
  • Commercial launch: September 2020
  • Total FTEs: 35 (as of 9/15/22)
  • 2022 Revenue: $2M
  • Sensor users: 15,800 to date, 1,800 in US clinical trial
  • Sensors per customer per year: 5.71
  • Third-party data integration: over 200M potential collective users

Customers


Recognized by world-class athletes for delivering results


—

Business model


Subscription model,  strong sales & a proven B2B strategy


B2B strategy refined in Europe


  • Supersapiens’ initial European GTM targeted individual athletes, using brand ambassadors and event sponsorship to grow brand awareness and customers location-by-location
  • Through early learnings, Supersapiens pivoted to B2B, targeting professional teams, collegiate and amateur athletics, coaches, trainers, and nutritionists, reaching a large network with fewer direct sale touch points
  • The current focus is on pro and amateur athletes to showcase the benefits and then expand to help every athlete become a better version of themselves

Market


Wearable, connected fitness is trending with consumers and investors

  • There is a dramatic rise in popularity of connected fitness and wearable technology
  • 1 in 5 Americans use a fitness monitoring device
  • By 2025, an estimated 46.3 US adults will use a connected fitness platform at least once a month

2022 Wearable Device spending by type


US connected fitness users


Investor focus in wearable
technology is increasing





  • Series A rounds have increased from less than $6M to greater than $20M over the last 10 years
  • Whoop and Oura raised their Series A rounds 9 and 6 years ago, and have since raised $407M and $275M to date
  • Levels recently raised a $38M Series A at a $300M post-money



Series A post-money valuations


Competition


Outperforming every
similar technology



Vision and strategy


Leveraging athletes to show that glucose matters to all


Supersapiens Sport


The world looks to professional sports teams and athletes for inspiration — Supersapiens is positioned to help the world see that glucose matters for all. By using sport as a platform, Supersapiens will help educate all levels of athletes about why glucose matters and motivate them to get or stay active. Fans will want to be like their heroes; collectively we are all Supersapiens.

Supersapiens Sport growth strategy

  • The US is the largest market for wearables and sports, presenting a huge opportunity for exponential growth
  • Supersapiens users have been primarily individuals competing in long-distance sports (marathons, triathlons, Ironman competitions)
  • There is a growing interest among more traditional team sports (basketball, football, soccer, etc.) as well as vocations that require sharp focus (military, medical, transportation, heavy-equipment) 
  • Using Supersapiens’ data can benefit anyone who wants to be at the top of their game, mentally and physically


Funding


Strategic partnership with industry leader Abbott


  • Abbott launched the first continuous glucose monitor device in 2013 and continues to be a pioneer and industry leader in the space.
  • Abbott has spent decades and $3B refining its CGM biosensors that necessitate accuracy and reliability for the diabetic community.
  • In 2020, Abbott launched the first over-the-counter biosensor for the sports market in an exclusive partnership with Supersapiens. The partnership makes Supersapiens the only platform that directly integrates with Libre Sense sensor – allowing Supersapiens to scale quickly with unlimited access to best-in-class biosensors without the product and technology barriers its competitors face.
  • Glucose is just the beginning — the companies are researching, developing, and innovating together to create new technology with analyses/insights beyond glucose.
  • This partnership is protected by a multi-year contract.


Backed by leading medical professionals





Use of proceeds


Supersapiens is seeking to raise up to $40M for continued operations and US launch. The raise will allow Supersapiens management to:

  • Focus on operations and growth
  • Explore strategic acquisition opportunities and invest in continued innovation to add to the platform’s capabilities
  • Invest in the team’s salesforce and R&D

Founders


Led by industry veterans and founders in  healthcare, sports, and finance


Pioneered by passion


The Supersapiens founders embody what it means to put everything on the line, celebrate achievements, reflect on shortcomings, and bring an idea — the future — a little closer.

For decades, Founder and CEO Phil Southerland worked with Abbott and his professional cycling team to pioneer continuous glucose monitoring (CGM) technology. Together, they helped shape CGM to become what it is today.

Years later, with proven and accurate sensors, Supersapiens partnered with Abbott to build the world’s only real-time energy management system for athletes. In addition to Supersapiens, Phil is the Founder of the non-profit Team Type 1 Foundation, Co- Founder of Team Novo Nordisk, and author of the book, “Not Dead Yet.”

Supersapiens believes that everyone has what it takes to achieve their goals — and both data and the power of community will help them achieve it faster. 

Supersapiens is here to help athletes unlock their potential.

Deal terms


Security Instrument
Crowd Convertible Promissory Note

Please see our FAQs for more details

Valuation Cap
$85M

The valuation cap is the maximum valuation at which the note can be converted into equity, protecting investors from excessive dilution if the company's value increases significantly.

Discount
20%

The discount rate is the percentage discount that the investor will receive when converting the note into equity, compared to the price paid by a later round of investors.

Interest Rate
8%

The interest rate is the percentage that the investor will earn on the note until it matures or is converted into equity.

Maturity
24 Months

The maturity date is the date on which the note must be repaid, either with interest or converted into equity.


Minimum investment
$100
The smallest investment amount that Supersapiens is accepting.
Learn more
Maximum investment
$123.5K
The largest investment amount that Supersapiens is accepting.
Learn more
Deadline
April 29, 2023
Supersapiens needs to reach their minimum funding goal before the deadline (). If they don’t, all investments will be refunded.
Learn more
How it works

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by TT1 Products, Inc. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Supersapiens Security TT1 Products (Supersapiens) Form C .pdf

About Supersapiens

Legal Name
TT1 Products, Inc
Founded
Jul 2019
Form
Delaware Corporation
Employees
12
Website
supersapiens.com
Social Media
Headquarters
Google Map location of of Supersapiens
2144 Hills Avenue Northwest Ste A , Atlanta, GA
Headquarters
2144 Hills Avenue Northwest, Ste A, Atlanta, GA, United States 30318

Supersapiens Team
Everyone helping build Supersapiens , not limited to employees

Profile picture of Phil Southerland
Phil Southerland
Founder and CEO
Profile picture of Jay Robbins
Jay Robbins
Co-Founder and CFO
Profile picture of Howard Zisser, MD
Howard Zisser, MD
CSO
Profile picture of Chris Belli
Chris Belli
COO
Profile picture of Fitzalan Crowe
Fitzalan Crowe
Co-Founder and Chief of Staff
Profile picture of Jared Fair
Jared Fair
SVP of Finance and Operations
Profile picture of Kristina  Skroce
Kristina Skroce
Exercise Physiologist
Profile picture of Andrea Zignoli, PhD
Andrea Zignoli, PhD
Data Analyst
Profile picture of Bobby Julich, OLY
Bobby Julich, OLY
Performance Elite Athletes & Coaches
9 more team members
Phil Southerland
Founder and CEO
Jay Robbins
Co-Founder and CFO
Howard Zisser, MD
CSO
Chris Belli
COO
Fitzalan Crowe
Co-Founder and Chief of Staff
Jared Fair
SVP of Finance and Operations
Kristina Skroce
Exercise Physiologist
Andrea Zignoli, PhD
Data Analyst
Bobby Julich, OLY
Performance Elite Athletes & Coaches

Press

Supersapiens Glucose Monitoring System Subscription (Mont...
road.cc road.cc
·
Mar 18, 2023

The Supersapiens Glucose Monitoring System claims to be the world's only minute-by-minute energy management system. Does ...

What are Continuous Glucose Monitors? Explaining their us...
cyclingnews.com cyclingnews.com
·
Mar 16, 2023

(Image credit: Supersapiens) During her long-range solo breakaway in the latter part of Strade Bianche, Kristen Faulkner ...

NBA Launchpad selects seven companies to research and dev...
NBA.com: NBA Communications NBA.com: NBA Communications
·
Feb 28, 2023

NEW YORK - The National Basketball Association today announced it has selected seven companies for the second installment...

Supersapiens glucose monitor review - it's cutting edge t...
cyclingweekly.com cyclingweekly.com
·
Feb 16, 2023

Supersapiens is a relatively new brand in the world of elite sport, but it has become a well-known name after appearing o...

Supersapiens Wins Inaugural Global Triathlon Award
Endurance Sportswire Endurance Sportswire
·
Jan 23, 2023

The Global Triathlon Awards selected Supersapiens as the 2023 winner for Outstanding Tech Product at its inaugural awards...

Garmin's new heart-rate monitor, stainless steel bottle c...
BikeRadar BikeRadar
·
Dec 23, 2022

Christmas truly has come early to you lucky BikeRadar readers. First Look Friday has fallen on Christmas Eve-eve here in ...

The bonk prevention edition! Five cool things coming soon...
road.cc road.cc
·
Dec 12, 2022

We've all 'hit the wall' or cracked pretty badly when out on a ride, so this week's highlights from our bulging pile of b...

Supersapiens' continuous glucose monitoring system can he...
T3 T3
·
Oct 4, 2022

Runners and cyclists love their gadgets; the more accurately we can monitor our performance, the better. Nowadays, you ca...

Supersapiens welcomes Chris Froome as technical advisor a...
BikeBiz BikeBiz
·
Sep 10, 2021

Supersapiens has welcomed Chris Froome as a technical advisor and investor. Froome will be featured in Supersapiens' mark...

Team Jumbo-Visma Extends Partnership with Supersapiens
Prnewswire Prnewswire

ATLANTA, June 9, 2022 /PRNewswire/ -- Team Jumbo-Visma is pleased to announce that Supersapiens, the world's first energy...

Show all
Logo of Supersapiens

Supersapiens

Supersapiens successfully raised $1,235,000 from 376 investors on April 29, 2023
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Instruments
  • Crowd SAFE
  • Tokenized assets
Company
  • About
  • Journal
  • Events
  • Contact
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.

All related securities activity is conducted by OpenDeal Broker LLC a registered broker-dealer, Member of FINRA and SiPC, an affiliate of OpenDeal Inc. and OpenDeal Portal LLC, located at 149 5th Avenue, 10th Floor, New York, NY 10010. Please check our background on FINRA’s BrokerCheck.

Certain pages discussing the mechanics and providing educational materials regarding regulation crowdfunding offerings may refer to OpenDeal Broker LLC and OpenDeal Portal LLC collectively as “Republic”, solely for explanatory purposes.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC make investment recommendations and no communication, through this Site, or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Investment opportunities posted on this Site are private placements of securities that are not publicly traded, involve a high degree of risk, may lose value including the total loss of invested capital, are subject to holding period requirements and are intended for investors who do not need a liquid investment. Past performance is not indicative of future results. Investors must be able to afford the loss of their entire investment. Only qualified investors, who understand the risks of early-stage investment and who meet the Republic's investment criteria may invest. Investors may be restricted to only Accredited Investors or non-U.S. persons, to invest in offerings hosted by OpenDeal Broker. Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC, nor any of their officers, directors, agents and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this Site or the use of information on this site. Offers to sell securities can only be made through official offering documents that contain important information about the investment and the issuers, including risks. Investors should carefully read the offering documents. Investors should conduct their own due diligence and are encouraged to consult with their tax, legal and financial advisors.

By accessing the Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Please also see OpenDeal Broker’s Business Continuity Plan and Additional Risk Disclosures. All issuers offering securities under regulation crowdfunding as hosted by OpenDeal Portal LLC are listed on the All Companies Page. The inclusion or exclusion of an issuer on the Platform Page and/or Republic’s Homepage, which includes offerings conducted under regulation crowdfunding as well as other exemptions from registration, is not based upon any endorsement or recommendation by OpenDeal Inc, OpenDeal Portal LLC, or OpenDeal Broker LLC, nor any of their affiliates, officers, directors, agents, and employees. Rather, issuers of securities may, in their sole discretion, opt-out of being listed on the Platform Page and Homepage.

Investors should verify any issuer information they consider important before making an investment.

Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. Therefore, when you use the Services we will ask for your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver's license, passport or other identifying documents.

Republic and its affiliates are not and do not operate or act as a bank. Certain banking services are provided by BankProv, member FDIC / member DIF. FDIC coverage only applies in the event of bank failure. Digital (crypto) assets and investment products are not insured by the FDIC, may lose value, and are not deposits or other obligations of BankProv and are not guaranteed by BankProv. Terms and conditions apply.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC